Allosteric inhibitor of RAD52; inhibits RAD52 binding to single strand DNA binding domains (IC50 = 1.1 μM). Selectively inhibits proliferation of BRCA-deficient cancer cells in vitro. Also inhibits APE1.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 213.19. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.69 mL||23.45 mL||46.91 mL|
|5 mM||0.94 mL||4.69 mL||9.38 mL|
|10 mM||0.47 mL||2.35 mL||4.69 mL|
|50 mM||0.09 mL||0.47 mL||0.94 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Wilson DM 3rd et al (2010) Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol.Life Sci. 67 3621 PMID: 20809131
Simeonov et al (2009) Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One 4 e5740 PMID: 19484131
Chandramouly et al (2015) Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chem.Biol. 22 1491 PMID: 26548611
If you know of a relevant reference for 6-Hydroxy-DL-DOPA, please let us know.
View Related Products by Product Action
Keywords: 6-Hydroxy-DL-DOPA, supplier, Allosteric, inhibitors, RAD52, APE1, BRCA, deficient, cancer, synthetic, lethality, inhibits, DNA,, RNA, and, Protein, Synthesis, DNA,, RNA, and, Protein, Synthesis, Tocris Bioscience
Citations for 6-Hydroxy-DL-DOPA
Citations are publications that use Tocris products.
Currently there are no citations for 6-Hydroxy-DL-DOPA. Do you know of a great paper that uses 6-Hydroxy-DL-DOPA from Tocris? If so please let us know.